Compass Biotechnologies, Inc.  

(Public, OTCMKTS:COBI)   Watch this stock  
Find more results for OTC:COBI
0.00000 (0.00%)
Delayed:   10:33AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.00
Open 0.00
Vol / Avg. 300,000.00/6.72M
Mkt cap 285,570.00
P/E     -
Div/yield     -
EPS -0.01
Shares 1.43B
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Jul '12) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -18.11% -124.06%
Return on average equity - -
Employees 2 -
CDP Score - -


9650 - 20 Avenue
+1-780-4692975 (Phone)
+1-780-6697633 (Fax)

Website links


Compass Biotechnologies Inc., formerly Cyplasin BioMedical, Ltd., is a development-stage company. The Company is a biotechnology research and development company. The Company is focusing on the development and commercialization of generic, bio-similar and bio-better drug products. The Company is engaged in the business of developing its licenses for patents pertaining to the technology utilized in the prevention and treatment of hepatitis C. The Company's subsidiary is 1WorldDirect US Inc.

Officers and directors

Garth Likes Chairman of the Board
Joseph Sinkule Chief Executive Officer, President, Chief Operating Officer, Director